Abstract:The WNT/β-catenin is among one of the most extensively studied cellular signaling pathways involved in the initiation and progression of several deadly cancers. It is now understood that the WNT/β-catenin signaling, during tumor progression operates in a very complex fashion beyond the earlier assumed simple WNT 'On' or 'Off' mode as it recruits numerous WNT ligands, receptors, transcriptional factors and also cross-talks with other signaling molecules including the noncanonical WNT regulators. WNT/β-catenin signaling molecules are often mutated in different cancers which makes them very challenging to inhibit and sometimes ranks them among the undruggable targets. Furthermore, due to the evolutionary conservation of this pathway, inhibiting WNT/β-catenin has caused significant toxicity in normal cells. These challenges are reflected in clinical trial data, where the use of WNT/β-catenin inhibitors as standalone treatments remains limited. In this review, we have highlighted the crucial functional associations of diverse WNT/β-catenin signaling regulators with cancer progression and the phenotypic switching of tumor cells. Next, we have shed light on the roles of WNT/β-catenin signaling in drug resistance, clonal evolution, tumor heterogeneity, and immune evasion. The present review also focuses on various classes of routine and novel WNT/β-catenin therapeutic regimes while addressing the challenges associated with targeting the regulators of this complex pathway. In the light of multiple case studies on WNT/β-catenin inhibitors, we also highlighted the challenges and opportunities for future clinical trial strategies involving these treatments. Additionally, we have proposed strategies for future WNT/β-catenin-based drug discovery trials, emphasizing the potential of combination therapies and AI/ML-driven prediction approaches. Overall, here we showcased the opportunities, possibilities, and potentialities of WNT/β-catenin signaling modulatory therapeutic regimes as promising precision cancer medicines for the future.

Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Targeting the β-catenin signaling for cancer therapy

Drug discovery efforts toward inhibitors of canonical Wnt/13-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010-2020)

The regulation of β-catenin activity and function in cancer: therapeutic opportunities

Targeting Wnt/β-Catenin Pathway for Drug Therapy

Wnt/β-catenin Singal Transduction Pathway and Colorectal Cancer

Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.

Pharmacological Inhibition of Β-Catenin/bcl9 Interaction Overcomes Resistance to Immune Checkpoint Blockades by Modulating T Reg Cells

Molecular docking-aided identification of small molecule inhibitors targeting β-catenin-TCF4 interaction

Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy through the Activation of Antigen Presentation of cDC1 Cells

Discovery of small molecule β-catenin suppressors that enhance immunotherapy

Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy

Targeting the Wnt/β-catenin signaling pathway in cancer

Discovery of small molecule modulators targeting β-catenin interactions using molecular docking and molecular dynamics strategy

Recent advances in -catenin/BCL9 protein-protein interaction inhibitors

Design, Synthesis and Biological Evaluation of Quercetin Derivatives As Novel Β-Catenin/b-cell Lymphoma 9 Protein−protein Interaction Inhibitors

Belling the "cat": Wnt/β-catenin signaling and its significance in future cancer therapies

Effect of Suppressing Tankyrases on Canonical Wnt Pathway: A New Target for the Treatment of Cancer

Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors